Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/1644
Title: Pde4 inhibition : An emerging therapeutic strategy in liver diseases
Authors: Grewal A S
Thapa K
Sharma N
Singh S
Singh R
Singh K
Arora S
Keywords: ALD (Alcohol liver disease)
CAMP
Liver fibrosis
NAFLD (Non-alcohol liver disease
)PDE4 inhibitors
PDEs
Issue Date: 2020
Publisher: Plant Archives
Abstract: The world has been reported with 2 million mortalities a year due to liver disease and the major concern is unavailability of clinically approved treatment for liver diseases; therefore, there is an urgent need of novel treatments and targets. Cyclic adenosine monophosphate (cAMP, a second messenger) implicated in controlling of various cellular operations such as cell differentiation, inflammation, lipid metabolism by influencing gene expression and is the protective pathway. During liver injury cAMP is degraded by phosphodiesterases (PDEs), therefore cAMP pathway is widely focused in liver damage to evaluate its biological function as therapeutic target, based on the state of liver. Recently inhibition of cAMP specific PDE4 has been reported as a novel target as PDE4 inhibition raises intracellular cAMP level that consequently modulates inflammatory responses. Currently PDE4 inhibitors are presented as modulators of intracellular signals and gene transcription for the pharmacotherapy of liver disease. The present review summarizes the part of cAMP signaling pathway in liver wellbeing and ailments including non-alcoholic fatty liver disease as well as alcoholic liver disease. This review also discusses PDE4 inhibition as remarkable therapeutic approach for these conditions. � 2020 Plant Archives. All rights reserved.
URI: http://www.plantarchives.org/SPL%20ISSUE%2020-2/380__2285-2290_.pdf
http://hdl.handle.net/123456789/1644
Appears in Collections:Journals

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.